{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:06:57Z","timestamp":1769738817874,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12032-021-01504-y","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T09:09:02Z","timestamp":1617959342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of interleukins and the widely studied TNF-\u03b1 in non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Kyle P.","family":"D\u2019mello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin C.","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-7374","authenticated-orcid":false,"given":"Yujiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"5","key":"1504_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1939-1676.1991.tb03135.x","volume":"5","author":"RE Elmslie","year":"1991","unstructured":"Elmslie RE, Dow SW, Ogilvie GK. Interleukins: biological properties and therapeutic potential. J Vet Intern Med. 1991;5(5):283\u201393. https:\/\/doi.org\/10.1111\/j.1939-1676.1991.tb03135.x.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","volume":"358","author":"MR Davis","year":"2015","unstructured":"Davis MR, Zhu Z, Hansen DM, Bai Q, Fang Y. The role of IL-21 in immunity and cancer. Cancer Lett. 2015;358(2):107\u201314. https:\/\/doi.org\/10.1016\/j.canlet.2014.12.047.","journal-title":"Cancer Lett"},{"key":"1504_CR3","unstructured":"Vaillant AAJ, Qurie A. Interleukin. StatPearls [Internet]. 2019."},{"issue":"7","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12032-016-0782-4","volume":"33","author":"VA Ding","year":"2016","unstructured":"Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-37 in cancer. Med Oncol. 2016;33(7):68. https:\/\/doi.org\/10.1007\/s12032-016-0782-4.","journal-title":"Med Oncol"},{"issue":"2","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2016.01.004","volume":"373","author":"DH Xu","year":"2016","unstructured":"Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer Lett. 2016;373(2):156\u201363. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.004.","journal-title":"Cancer Lett"},{"issue":"10","key":"1504_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/jir.2018.0089","volume":"38","author":"J Catalan-Dibene","year":"2018","unstructured":"Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Res. 2018;38(10):423\u201339. https:\/\/doi.org\/10.1089\/jir.2018.0089.","journal-title":"J Interferon Cytokine Res"},{"key":"1504_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2016.08.002","volume":"106","author":"NE Kelm","year":"2016","unstructured":"Kelm NE, Zhu Z, Ding VA, Xiao H, Wakefield MR, Bai Q, et al. The role of IL-29 in immunity and cancer. Crit Rev Oncol Hematol. 2016;106:91\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s12253-019-00665-6","volume":"26","author":"JE Lee","year":"2020","unstructured":"Lee JE, Zhu Z, Bai Q, Brady TJ, Xiao H, Wakefield MR, et al. The role of interleukin-9 in cancer. Pathol Oncol Res. 2020;26(4):2017\u201322. https:\/\/doi.org\/10.1007\/s12253-019-00665-6.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.21873\/anticanres.11405","volume":"37","author":"J Lin","year":"2017","unstructured":"Lin J, Zhu Z, Xiao H, Wakefield MR, Ding VA, Bai Q, et al. The role of IL-7 in immunity and cancer. Anticancer Res. 2017;37(3):963\u20137. https:\/\/doi.org\/10.21873\/anticanres.11405.","journal-title":"Anticancer Res"},{"issue":"1","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-017-0721-9","volume":"16","author":"S Setrerrahmane","year":"2017","unstructured":"Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017;16(1):153. https:\/\/doi.org\/10.1186\/s12943-017-0721-9.","journal-title":"Mol Cancer"},{"issue":"5","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2217\/imt.09.46","volume":"1","author":"T Yoshimoto","year":"2009","unstructured":"Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, Mizuguchi J. Interleukins and cancer immunotherapy. Immunotherapy. 2009;1(5):825\u201344. https:\/\/doi.org\/10.2217\/imt.09.46.","journal-title":"Immunotherapy"},{"issue":"11","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684\u201392. https:\/\/doi.org\/10.1038\/bjc.2011.450.","journal-title":"Br J Cancer"},{"issue":"9","key":"1504_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1542\/pir.2016-0152","volume":"38","author":"IN Buhtoiarov","year":"2017","unstructured":"Buhtoiarov IN. Pediatric lymphoma. Pediatr Rev. 2017;38(9):410\u201323. https:\/\/doi.org\/10.1542\/pir.2016-0152.","journal-title":"Pediatr Rev"},{"issue":"1","key":"1504_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/asheducation-2016.1.589","volume":"2016","author":"JT Sandlund","year":"2016","unstructured":"Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program. 2016;2016(1):589\u201397. https:\/\/doi.org\/10.1182\/asheducation-2016.1.589.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10091","key":"1504_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2.","journal-title":"Lancet"},{"key":"1504_CR16","doi-asserted-by":"crossref","unstructured":"Ansell SM, editor. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clinic Proceedings; Elsevier:2015.","DOI":"10.1016\/j.mayocp.2015.04.025"},{"issue":"6","key":"1504_CR17","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. https:\/\/doi.org\/10.1080\/2162402X.2016.1163462.","journal-title":"Oncoimmunology"},{"issue":"7","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1089\/dna.2011.1603","volume":"31","author":"H Song","year":"2012","unstructured":"Song H, Chen L, Cha Z, Bai J. Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol. 2012;31(7):1279\u201384. https:\/\/doi.org\/10.1089\/dna.2011.1603.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"1504_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/0471142735.im0718s35","volume":"35","author":"TL Whiteside","year":"2000","unstructured":"Whiteside TL. Measurement of cytotoxic activity of NK\/LAK cells. Curr Protoc Immunol. 2000;35(1):7\u201318.","journal-title":"Curr Protoc Immunol"},{"issue":"5625","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1126\/science.1085458","volume":"300","author":"AE Kelly-Welch","year":"2003","unstructured":"Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527\u20138. https:\/\/doi.org\/10.1126\/science.1085458.","journal-title":"Science"},{"key":"1504_CR21","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15038590","author":"HO Soydinc","year":"2016","unstructured":"Soydinc HO, Guney N, Basaran M, Duranyildiz D, Yasasever V. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin\u2019s lymphoma patients. Genet Mol Res. 2016. https:\/\/doi.org\/10.4238\/gmr.15038590.","journal-title":"Genet Mol Res"},{"issue":"1","key":"1504_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0014-5793(92)80909-z","volume":"307","author":"M Baggiolini","year":"1992","unstructured":"Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307(1):97\u2013101. https:\/\/doi.org\/10.1016\/0014-5793(92)80909-z.","journal-title":"FEBS Lett"},{"issue":"1","key":"1504_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cyto.2008.04.004","volume":"43","author":"HL Lee","year":"2008","unstructured":"Lee HL, Eom HS, Yun T, Kim HJ, Park WS, Nam BH, et al. Serum and urine levels of interleukin-8 in patients with non-Hodgkin\u2019s lymphoma. Cytokine. 2008;43(1):71\u20135. https:\/\/doi.org\/10.1016\/j.cyto.2008.04.004.","journal-title":"Cytokine"},{"issue":"5","key":"1504_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/mp.51.5.273","volume":"51","author":"MG Luciani","year":"1998","unstructured":"Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP. The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin\u2019s disease and in solid tumours. Mol Pathol. 1998;51(5):273\u20136. https:\/\/doi.org\/10.1136\/mp.51.5.273.","journal-title":"Mol Pathol"},{"issue":"5","key":"1504_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","volume":"10","author":"RC Russo","year":"2014","unstructured":"Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593\u2013619. https:\/\/doi.org\/10.1586\/1744666X.2014.894886.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1504_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","volume":"367","author":"MH Mannino","year":"2015","unstructured":"Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.009.","journal-title":"Cancer Lett"},{"issue":"3\u20134","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/10428199709051774","volume":"26","author":"J Cortes","year":"1997","unstructured":"Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 1997;26(3\u20134):251\u20139. https:\/\/doi.org\/10.3109\/10428199709051774.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1504_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.humimm.2016.03.006","volume":"77","author":"G Li","year":"2016","unstructured":"Li G, Li D. Relationship between IL-10 gene polymorphisms and the risk of non-Hodgkin lymphoma: a meta-analysis. Hum Immunol. 2016;77(5):418\u201325.","journal-title":"Hum Immunol"},{"issue":"3","key":"1504_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/ijms20030649","volume":"20","author":"K Yasuda","year":"2019","unstructured":"Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20(3):649. https:\/\/doi.org\/10.3390\/ijms20030649.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1504_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","volume":"7","author":"N Rothman","year":"2006","unstructured":"Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(05)70434-4.","journal-title":"Lancet Oncol"},{"key":"1504_CR31","doi-asserted-by":"publisher","first-page":"107602961984333","DOI":"10.1177\/1076029619843338","volume":"25","author":"P Patel","year":"2019","unstructured":"Patel P, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Markers of inflammation and infection in sepsis and disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2019;25:1076029619843338. https:\/\/doi.org\/10.1177\/1076029619843338.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1504_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2017.02.022","volume":"394","author":"DH Xu","year":"2017","unstructured":"Xu DH, Zhu Z, Xiao H, Wakefield MR, Bai Q, Nicholl MB, et al. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. Cancer Lett. 2017;394:43\u201351. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.022.","journal-title":"Cancer Lett"},{"issue":"12","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1490019.","journal-title":"J Immunol"},{"issue":"6","key":"1504_CR34","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509\u201321. https:\/\/doi.org\/10.1002\/jcp.27782.","journal-title":"J Cell Physiol"},{"key":"1504_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","volume":"38","author":"Y Guo","year":"2017","unstructured":"Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10\u201321.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"1504_CR36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1586\/1744666X.2014.973856","volume":"10","author":"TA Waldmann","year":"2014","unstructured":"Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014;10(12):1689\u2013701. https:\/\/doi.org\/10.1586\/1744666X.2014.973856.","journal-title":"Expert Rev Clin Immunol"},{"key":"1504_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","volume":"31","author":"M Patidar","year":"2016","unstructured":"Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev. 2016;31:49\u201359. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.06.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"1504_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1756-9966-29-121","volume":"29","author":"Y Zheng","year":"2010","unstructured":"Zheng Y, Yu K, Du J, Jiang L, Zhang S, Han Y, et al. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc\/CD28\/CD3zeta gene tranfected T cells. J Exp Clin Cancer Res. 2010;29(1):121. https:\/\/doi.org\/10.1186\/1756-9966-29-121.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1504_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/1471-2458-12-526","volume":"12","author":"AJ Carter","year":"2012","unstructured":"Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health. 2012;12(1):526. https:\/\/doi.org\/10.1186\/1471-2458-12-526.","journal-title":"BMC Public Health"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01504-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:59:46Z","timestamp":1671832786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01504-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01504-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"56"}}